ctDNA guides anti-EGFR rechallenge
Nature Reviews Clinical Oncology, Published online: 25 August 2022; doi:10.1038/s41571-022-00681-7ctDNA guides anti-EGFR rechallenge (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - August 25, 2022 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research
The KRYSTAL-1 study of adagrasib — a new trial for KRASG12C-mutated non-small-cell lung cancer
Nature Reviews Clinical Oncology, Published online: 23 August 2022; doi:10.1038/s41571-022-00676-4The development of covalent, allele-specific inhibitors of KRASG12C represents a major breakthrough in precision oncology. Herein we discuss recent data from the phase II KRYSTAL-1 trial of adagrasib in KRASG12C-mutated non-small-cell lung cancer (NSCLC). This trial showed responses in a subset of patients, including among those with brain metastases, and offers exploratory insights into potential biomarkers of response. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - August 23, 2022 Category: Cancer & Oncology Authors: Yonina R. Murciano-Goroff Piro Lito Source Type: research
ARROW: pralsetinib hits target across cancers
Nature Reviews Clinical Oncology, Published online: 23 August 2022; doi:10.1038/s41571-022-00683-5ARROW: pralsetinib hits target across cancers (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - August 23, 2022 Category: Cancer & Oncology Authors: David Killock Source Type: research
Author Correction: Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management
Nature Reviews Clinical Oncology, Published online: 15 August 2022; doi:10.1038/s41571-022-00680-8Author Correction: Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - August 15, 2022 Category: Cancer & Oncology Authors: Alissa J. Cooper Lecia V. Sequist Jessica J. Lin Source Type: research
Promising OS with oncolytic virotherapy
Nature Reviews Clinical Oncology, Published online: 15 August 2022; doi:10.1038/s41571-022-00678-2Promising OS with oncolytic virotherapy (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - August 15, 2022 Category: Cancer & Oncology Authors: David Killock Source Type: research
When an embarrassment of riches isn’t enough
Nature Reviews Clinical Oncology, Published online: 08 August 2022; doi:10.1038/s41571-022-00670-wData on a new treatment approach utilizing bispecific monoclonal antibodies targetting B-cell maturation antigen (BCMA) were recently published, yielding very encouraging results in the setting of relapsed and/or refractory multiple myeloma (RRMM). How to safely and effectively deliver this treatment to patients and where it fits in the RRMM treatment paradigm are important questions for the future. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - August 8, 2022 Category: Cancer & Oncology Authors: Krina Patel Sagar Lonial Source Type: research
KEYNOTE-355 — OS benefit now reported
Nature Reviews Clinical Oncology, Published online: 02 August 2022; doi:10.1038/s41571-022-00674-6KEYNOTE-355 — OS benefit now reported (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - August 2, 2022 Category: Cancer & Oncology Authors: Diana Romero Source Type: research
Liso-cel effective in R/R LBCL
Nature Reviews Clinical Oncology, Published online: 02 August 2022; doi:10.1038/s41571-022-00673-7Liso-cel effective in R/R LBCL (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - August 2, 2022 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research
Circulating tumour DNA — looking beyond the blood
Nature Reviews Clinical Oncology, Published online: 01 August 2022; doi:10.1038/s41571-022-00660-yAdvances in circulating tumour DNA (ctDNA) detection and analysis are beginning to be implemented in clinical practice. Nonetheless, much of this development has thus far focused on plasma ctDNA. Theoretically, all bodily fluids, including urine, cerebrospinal fluid, saliva, pleural fluid and others, can also contain measurable ctDNA and can provide several advantages over the reliance on plasma ctDNA. In this Review, Tivey et al. describe the potential roles of ctDNA obtained from non-plasma sources in optimizing the outcomes...
Source: Nature Reviews Clinical Oncology - August 1, 2022 Category: Cancer & Oncology Authors: Ann Tivey Matt Church Dominic Rothwell Caroline Dive Natalie Cook Source Type: research
Defining clinically important overall survival thresholds: lessons from quality of life
Nature Reviews Clinical Oncology, Published online: 27 July 2022; doi:10.1038/s41571-022-00667-5In randomized controlled trials in oncology, changes in quality of life are usually reported together with a description of the differences considered a priori to be clinically important, but overall survival outcomes are rarely provided together with information of what constitutes a clinically meaningful threshold. In this Comment, we propose the benefits that could be derived from reporting overall survival in a similar way to quality of life. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - July 27, 2022 Category: Cancer & Oncology Authors: Bishal Gyawali Christopher M. Booth Source Type: research
Craniospinal irradiation improves leptomeningeal metastasis control
Nature Reviews Clinical Oncology, Published online: 26 July 2022; doi:10.1038/s41571-022-00669-3Craniospinal irradiation improves leptomeningeal metastasis control (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - July 26, 2022 Category: Cancer & Oncology Authors: Diana Romero Source Type: research
Tasadenoturev active in DIPG
Nature Reviews Clinical Oncology, Published online: 22 July 2022; doi:10.1038/s41571-022-00666-6Tasadenoturev active in DIPG (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - July 22, 2022 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research
The oligometastatic spectrum in the era of improved detection and modern systemic therapy
Nature Reviews Clinical Oncology, Published online: 12 July 2022; doi:10.1038/s41571-022-00655-9The oligometastatic state is generally considered to constitute an intermediate point along the spectrum of cancer dissemination at which the metastatic burden is limited and local ablative therapies can result in meaningful clinical benefit, and possibly even cure. In this Review, Katipally et al. reframe the oligometastatic phenotype as a dynamic state that expands beyond merely the number or size of metastases. They highlight important risk factors defining the metastatic spectrum that can inform both staging and therapy, and...
Source: Nature Reviews Clinical Oncology - July 12, 2022 Category: Cancer & Oncology Authors: Rohan R. Katipally Sean P. Pitroda Aditya Juloori Steven J. Chmura Ralph R. Weichselbaum Source Type: research
Overall survival as a primary end point in multiple myeloma trials
Nature Reviews Clinical Oncology, Published online: 12 July 2022; doi:10.1038/s41571-022-00665-7Median overall survival for patients with newly diagnosed multiple myeloma may surpass ten years. Nonetheless, many patients face considerable treatment-related morbidity and relapsed disease. Owing to this typically long overall survival, most multiple myeloma trials now use progression-free survival as their primary end point. In this Comment, we highlight circumstances in which this end point does not best answer the questions that various trials seek to investigate. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - July 12, 2022 Category: Cancer & Oncology Authors: Edward R. Scheffer Cliff Ghulam Rehman Mohyuddin Source Type: research
When can we be confident of surgical cure with ctDNA?
Nature Reviews Clinical Oncology, Published online: 07 July 2022; doi:10.1038/s41571-022-00664-8Tracking circulating tumour DNA (ctDNA) after surgery holds promise for patient management and therapeutic intervention in non-small-cell lung cancer (NSCLC). A study published by Zhang and colleagues tracks ctDNA from 261 patients with stages I–III NSCLC and suggests that the likelihood of disease relapse decreases for high-risk stage II/III patients after 18 months without ctDNA detection. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - July 7, 2022 Category: Cancer & Oncology Authors: Alexander Frankell Mariam Jamal-Hanjani Source Type: research
